NCT02628067 2025-09-22KEYNOTE 158Merck Sharp & Dohme LLCPhase 2 Active not recruiting1,609 enrolled 5 FDA
NCT03043313 2024-11-26Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal CancerSeagen Inc.Phase 2 Completed117 enrolled 21 charts 1 FDA